Prabhat Divya, Sholapuri Deepa, Uchit Ganesh
1Bhatia Hospital, Mumbai, India.
2B.J. Wadia Hospital, Mumbai, India.
Indian J Otolaryngol Head Neck Surg. 2019 Nov;71(Suppl 3):2096-2105. doi: 10.1007/s12070-018-1500-7. Epub 2018 Sep 27.
Despite high prevalence and impact on quality of life, Allergic Rhinitis (AR) is undertreated. Furthermore, existence of a relationship between AR and upper respiratory tract infection (URTI) is less explored. This Pan-India survey intended to assess physicians' perception about AR and URTI, and management practices in Indian setting. This questionnaire-based survey was conducted by telephonically interviewing 300 physicians [Consultant Physicians (CP): 33%; General Physicians (GP): 32%; ENT surgeons: 16%; pediatricians: 11%; allergy specialists: 8%] across India. CPs (33%) and GPs (32%) treated more AR patients in a month, versus other specialties. According to physicians, about 29.6% of patients with AR develop URTI in a month. Majority of the physicians (98%) believed that recurrent URTI can be considered as an indicator of undiagnosed AR. Majority of the physicians (98%) also considered AR to be a predisposing factor for increased risk of URTI. About 62% agreed that prompt diagnosis and treatment of AR can reduce the risk of complications such as URTI. Most preferred first- and second-line of treatment (alone or in combination) in AR management were oral antihistamines (41%) and intranasal corticosteroids (40%), respectively. Similar treatment preferences were observed irrespective of physicians' specialization and years of experience. This survey sheds light on the need to implement clear guidelines for the diagnosis and management of AR.
尽管变应性鼻炎(AR)患病率高且对生活质量有影响,但治疗不足。此外,AR与上呼吸道感染(URTI)之间的关系较少被探究。这项全印度调查旨在评估医生对AR和URTI的认知以及印度背景下的管理实践。这项基于问卷的调查通过电话采访印度各地的300名医生进行[顾问医师(CP):33%;全科医生(GP):32%;耳鼻喉科外科医生:16%;儿科医生:11%;过敏专科医生:8%]。与其他专科相比,CP(33%)和GP(32%)每月治疗的AR患者更多。据医生称,约29.6%的AR患者在一个月内会患上URTI。大多数医生(98%)认为复发性URTI可被视为未确诊AR的一个指标。大多数医生(98%)也认为AR是URTI风险增加的一个易感因素。约62%的人同意AR的及时诊断和治疗可降低诸如URTI等并发症的风险。AR管理中最常用的一线和二线治疗方法(单独或联合使用)分别是口服抗组胺药(41%)和鼻内皮质类固醇(40%)。无论医生的专业和经验年限如何,都观察到了类似的治疗偏好。这项调查揭示了为AR的诊断和管理制定明确指南的必要性。